Hypercalcemia of Malignancy

  • F. Raue

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 137)

Table of contents

  1. Front Matter
    Pages I-VII
  2. Biological Aspects

  3. Clinical Aspects

  4. Back Matter
    Pages 161-165

About this book


Hypercalcemia is the most common life-threatening metabolic disorder associated with cancer. The pathophysiological, epidemiological and clinical aspects of hypercalcemia of malignancy are presented in this issue, with a focus on the recently discovered humoral factor responsible for the development of hypercalcemia. With a better understanding of the pathophysiology of this condition and the development of new potent drugs, capable of inhibiting bone resorption, especially bisphosphonates, the clinician will be more successful in correcting hypercalcemia in the great majority of patients.


Bisphosphonate Knochenmetastasen Malignancy Parathormon-related Protein Zytokine bisphosphonates bone metastases cancer cytokines hormones metastasis osteolytic lesions parathyroid horman-related protein

Editors and affiliations

  • F. Raue
    • 1
  1. 1.Innere Medizin IMedizinische UniversitätsklinikHeidelbergGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-85075-2
  • Online ISBN 978-3-642-85073-8
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology